Researchers engineered a tandem thymosin beta-4 (tTB4) peptide that significantly outperformed the original thymosin beta-4 in promoting corneal wound healing. The engineered peptide binds two actin molecules simultaneously, enhancing cellular migration and tissue repair. In mouse studies, tTB4 accelerated corneal healing after chemical burns and reduced scarring more effectively than standard thymosin. The tandem design also enables bacterial production, making it more cost-effective than current peptide synthesis methods.
